Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 87

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 87
---
 small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger
opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by Biodexa are likely
to be dilutive. The Directors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially
available to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be
no assurance that any alternative courses of action to finance the Company would be successful.

This requirement for additional financing
in the short term represents a material uncertainty that may cast significant doubt upon the Group and Parent Company’s ability
to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the
Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances,
we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared
on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to current liabilities.

The following table sets out the contractual
maturities (representing undiscounted contractual cash-flows) of financial liabilities:

  Schedule of contractual maturities of financial liabilities                                          
  2024                                                                                                 
  Trade and other payables                                         1,986          –      –        –    
  Deferred considerations                                            178        533      711      711  
  Promissory note                                                      –        479      –        –    
  Lease liabilities                                                   47        142      111      –    
  Total                                                            2,211      1,154      822      711  

  2023                          Up to 3      Between       Between           
                                 months                    1 and 2           
                                             3 and 12                        
                                  £’000                    years             
                                             months                          
                                                           £’000             
                                             £’000                           
  Trade and other payables        1,178      –             –            –    
 ─────────────────────────────────────────────────────────────────────────────
  Lease liabilities                  47      141           189          112  
  Total                           1,225      141           189          112  

  2022                          Up to 3      Between       Between           
                                 months                    1 and 2